MA42196A - Particules de fumarate de diméthyle et leurs compositions pharmaceutiques - Google Patents
Particules de fumarate de diméthyle et leurs compositions pharmaceutiquesInfo
- Publication number
- MA42196A MA42196A MA042196A MA42196A MA42196A MA 42196 A MA42196 A MA 42196A MA 042196 A MA042196 A MA 042196A MA 42196 A MA42196 A MA 42196A MA 42196 A MA42196 A MA 42196A
- Authority
- MA
- Morocco
- Prior art keywords
- pharmaceutical compositions
- dimethyl fumarate
- fumarate particles
- particles
- dimethyl
- Prior art date
Links
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 title 1
- 229960004419 dimethyl fumarate Drugs 0.000 title 1
- 239000002245 particle Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562181061P | 2015-06-17 | 2015-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42196A true MA42196A (fr) | 2018-04-25 |
Family
ID=56292916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA042196A MA42196A (fr) | 2015-06-17 | 2016-06-15 | Particules de fumarate de diméthyle et leurs compositions pharmaceutiques |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11291642B2 (fr) |
| EP (1) | EP3310341A1 (fr) |
| JP (2) | JP2018517735A (fr) |
| KR (1) | KR20180018711A (fr) |
| CN (1) | CN107920997A (fr) |
| AU (2) | AU2016279997B2 (fr) |
| CA (1) | CA2989581A1 (fr) |
| EA (1) | EA201890068A1 (fr) |
| HK (1) | HK1254054A1 (fr) |
| IL (1) | IL256296A (fr) |
| MA (1) | MA42196A (fr) |
| MX (1) | MX387092B (fr) |
| WO (1) | WO2016205270A1 (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180318246A1 (en) * | 2015-10-28 | 2018-11-08 | Sun Pharmaceutical Industries Limited | Pharmaceutical compositions of dimethyl fumarate |
| JP6902043B2 (ja) * | 2016-02-11 | 2021-07-14 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | フマル酸ジメチルを含む医薬ビーズ製剤 |
| CN111163760A (zh) * | 2017-10-02 | 2020-05-15 | 诺华股份有限公司 | 用于制备药物产品的方法 |
| US11318682B2 (en) | 2018-04-06 | 2022-05-03 | Hewlett-Packard Development Company, L.P. | Three-dimensional (3D) object printing based on build material permeability |
| JP7564805B2 (ja) * | 2018-10-05 | 2024-10-09 | アイエスピー インヴェストメンツ エルエルシー | 水溶性セルロースエーテルを含有する平滑な高固形分フィルムコーティング組成物、その調製方法およびその使用方法 |
| TR201818293A2 (tr) * | 2018-11-30 | 2020-06-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Di̇meti̇l fumarat i̇çeren geci̇kmeli̇ salim sağlayan kapsül |
| WO2020160323A2 (fr) * | 2019-01-31 | 2020-08-06 | Elektrofi, Inc. | Formation et morphologie de particules |
| EP3941445A4 (fr) * | 2019-03-20 | 2023-08-02 | Lyndra Therapeutics, Inc. | Capsules et enrobages de capsules pour formes posologiques à résidence gastrique |
| US20220192995A1 (en) * | 2019-03-20 | 2022-06-23 | Lyndra Therapeutics, Inc. | Coatings for gastric residence dosage forms |
| EP4247354A4 (fr) * | 2020-11-18 | 2025-02-19 | Fb-Hrs, Llc | Compositions contenant du dofétilide et de la mexilétine et leurs utilisations |
| CN116887866A (zh) | 2020-12-03 | 2023-10-13 | 巴特尔纪念研究院 | 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法 |
| JP2024516108A (ja) | 2021-04-07 | 2024-04-12 | バテル・メモリアル・インスティテュート | 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術 |
| EP4346796A4 (fr) | 2021-06-04 | 2025-04-30 | Zim Laboratories Limited | Compositions à libération retardée de fumarate de diméthyle |
| US11590071B2 (en) * | 2021-07-06 | 2023-02-28 | King Abdulaziz University | Injectable drug delivery implant composition and method of use thereof |
| WO2025072751A1 (fr) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Compositions de nanoparticules polymères pour l'expression in vivo de polypeptides |
| WO2025090498A1 (fr) * | 2023-10-23 | 2025-05-01 | Isp Investments Llc | Sels d'acides gras à chaîne moyenne encapsulés et formes posologiques solides orales dérivées de ceux-ci |
| WO2025122954A1 (fr) | 2023-12-08 | 2025-06-12 | Battelle Memorial Institute | Utilisation de nanostructures d'origami d'adn pour systèmes de stockage de données basés sur des informations moléculaires |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2725623A1 (fr) | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| IL133196A0 (en) | 1999-11-29 | 2001-03-19 | Yissum Res Dev Co | Gastroretentive controlled release pharmaceutical dosage forms |
| DE10101307A1 (de) * | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
| US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| DK1799196T3 (en) * | 2004-10-08 | 2016-08-15 | Forward Pharma As | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
| PL1981465T3 (pl) | 2006-01-18 | 2016-03-31 | Intec Pharma Ltd | Metoda wytwarzania przyrządów do podawania środka przyjmowanego doustnie |
| CA2721493C (fr) * | 2008-04-18 | 2017-11-28 | Intec Pharma Ltd. | Administration de medicament a retention gastrique carbicopa - levodopa |
| CN102369000A (zh) * | 2009-01-09 | 2012-03-07 | 前进制药公司 | 包含一种或多种富马酸酯的药用组合物 |
| CN109044985A (zh) * | 2009-01-09 | 2018-12-21 | 前进制药知识产权有限公司 | 包含溶蚀骨架中的一种或多种富马酸酯的药物制剂 |
| US9422226B2 (en) * | 2011-06-08 | 2016-08-23 | Biogen Ma Inc. | Process for preparing high purity and crystalline dimethyl fumarate |
| WO2013076216A1 (fr) * | 2011-11-24 | 2013-05-30 | Synthon Bv | Libération contrôlée de particules comprenant du diméthylfumarate |
| MX370785B (es) | 2012-02-07 | 2020-01-06 | Biogen Ma Inc | Composiciones farmacéuticas que contienen fumarato de dimetilo. |
| WO2015042294A1 (fr) * | 2013-09-18 | 2015-03-26 | Xenoport, Inc. | Compositions de nanoparticules de fumarate de diméthyle |
| IN2013MU03070A (fr) * | 2013-09-25 | 2015-07-17 | Glenmark Pharmaceuticals Ltd | |
| EP3079663A1 (fr) * | 2013-12-13 | 2016-10-19 | Biogen MA Inc. | Forme pharmaceutique à libération contrôlée pour administration une fois par jour de fumarate de diméthyle |
| WO2015130998A1 (fr) * | 2014-02-28 | 2015-09-03 | Banner Life Sciences Llc | Capsules molles entériques à libération contrôlée d'esters de fumarate |
-
2016
- 2016-06-15 MX MX2017016509A patent/MX387092B/es unknown
- 2016-06-15 HK HK18113117.1A patent/HK1254054A1/zh unknown
- 2016-06-15 KR KR1020187001091A patent/KR20180018711A/ko not_active Ceased
- 2016-06-15 JP JP2017565133A patent/JP2018517735A/ja active Pending
- 2016-06-15 CN CN201680047251.2A patent/CN107920997A/zh active Pending
- 2016-06-15 EP EP16733793.0A patent/EP3310341A1/fr not_active Withdrawn
- 2016-06-15 MA MA042196A patent/MA42196A/fr unknown
- 2016-06-15 US US15/737,011 patent/US11291642B2/en active Active
- 2016-06-15 AU AU2016279997A patent/AU2016279997B2/en not_active Ceased
- 2016-06-15 EA EA201890068A patent/EA201890068A1/ru unknown
- 2016-06-15 CA CA2989581A patent/CA2989581A1/fr active Pending
- 2016-06-15 WO PCT/US2016/037486 patent/WO2016205270A1/fr not_active Ceased
-
2017
- 2017-12-13 IL IL256296A patent/IL256296A/en unknown
-
2021
- 2021-11-12 JP JP2021184469A patent/JP2022042512A/ja active Pending
-
2022
- 2022-01-12 AU AU2022200155A patent/AU2022200155A1/en not_active Abandoned
- 2022-02-22 US US17/677,204 patent/US20220362195A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016205270A1 (fr) | 2016-12-22 |
| US20220362195A1 (en) | 2022-11-17 |
| MX387092B (es) | 2025-03-19 |
| EA201890068A1 (ru) | 2018-09-28 |
| CA2989581A1 (fr) | 2016-12-22 |
| AU2016279997A1 (en) | 2018-01-18 |
| WO2016205270A8 (fr) | 2017-01-19 |
| MX2017016509A (es) | 2018-08-16 |
| AU2016279997B2 (en) | 2021-10-21 |
| US11291642B2 (en) | 2022-04-05 |
| KR20180018711A (ko) | 2018-02-21 |
| AU2022200155A1 (en) | 2022-02-10 |
| JP2018517735A (ja) | 2018-07-05 |
| US20190070143A1 (en) | 2019-03-07 |
| IL256296A (en) | 2018-02-28 |
| HK1254054A1 (zh) | 2019-07-12 |
| CN107920997A (zh) | 2018-04-17 |
| JP2022042512A (ja) | 2022-03-14 |
| EP3310341A1 (fr) | 2018-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA42196A (fr) | Particules de fumarate de diméthyle et leurs compositions pharmaceutiques | |
| ZA201802125B (en) | Pharmaceutical composition and application thereof | |
| MA50541A (fr) | Formulations pharmaceutiques | |
| IL264065A (en) | Oral gastroretentive formulations and uses thes thereof | |
| EP3426348A4 (fr) | Dérivé de 3-désoxy et compositions pharmaceutiques associées | |
| DK3529248T3 (da) | Farmaceutiske sammensætninger | |
| EP3500255A4 (fr) | Compositions pharmaceutiques ophtalmiques et utilisations associées | |
| EP3541385A4 (fr) | Formulations pharmaceutiques | |
| MA42303A (fr) | Formulations pharmaceutiques | |
| EP3316685A4 (fr) | Compositions pharmaceutiques lyophilisées | |
| MA49837A (fr) | Compositions pharmaceutiques | |
| PL3145508T3 (pl) | Nanocząstki klewidypiny i ich kompozycje farmaceutyczne | |
| DK3280447T3 (da) | Farmaceutiske formuleringer | |
| EP3337463A4 (fr) | Formulations pharmaceutiques | |
| EP3302483A4 (fr) | Compositions pharmaceutiques et utilisation de celles-ci | |
| IL254711B (en) | History of diazepine-indole and medicinal preparations containing them | |
| PT3236938T (pt) | Composições farmacêuticas aquosas tópicas orais de flurbiprofeno e dexpantenol | |
| KR101809800B9 (ko) | 전복 내장 유래의 항알러지 효과를 가지는 펩타이드가 함유된 약학 조성물 | |
| EP3651800A4 (fr) | Formulations pharmaceutiques hydrocompressées | |
| EP3423041A4 (fr) | Compositions pharmaceutiques | |
| EP3528818A4 (fr) | Compositions pharmaceutiques | |
| MA42552A (fr) | Compositions pharmaceutiques de flurbiprofène et de tramadol | |
| MA43126A (fr) | Compositions pharmaceutiques de fumarate de diméthyle | |
| MA49625A (fr) | Compositions pharmaceutiques | |
| DK3558261T3 (da) | Farmaceutiske sammensætninger omfattende safinamid |